December 29, 2017 / 9:55 PM / 25 days ago

BRIEF-Thomas Clay Reports A 8.3 Pct Stake In Aviragen Therapeutics

Dec 29 (Reuters) - Aviragen Therapeutics Inc:

* THOMAS CLAY REPORTS A 8.3 PCT STAKE IN AVIRAGEN THERAPEUTICS INC AS OF DEC 29 - SEC FILING

* THOMAS CLAY- PURCHASED AVIRAGEN SHARES BASED ON BELIEF THAT WHEN PURCHASED, SHARES WERE “UNDERVALUED”, REPRESENTED ATTRACTIVE “INVESTMENT OPPORTUNITY”‍​

* THOMAS CLAY SAYS INTENDS TO SUBMIT DIRECTOR NOMINATIONS TO AVIRAGEN‘S BOARD TO BE CONSIDERED AT NEXT STOCKHOLDER MEETING HELD TO ELECT DIRECTORS

* THOMAS CLAY SAYS DO NOT BELIEVE PROPOSED MERGER BETWEEN AVIRAGEN, VAXART IS IN "BEST INTEREST" OF AVIRAGEN OR ITS STOCKHOLDERS Source text: (bit.ly/2ClVUO2) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below